A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate safety, pharmacokinetics, pharmacodynamics and to estimate efficacy of the new humanized monoclonal i.v. administered antibody CaCP29

Trial Profile

A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate safety, pharmacokinetics, pharmacodynamics and to estimate efficacy of the new humanized monoclonal i.v. administered antibody CaCP29

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs IFX 1 (Primary)
  • Indications Sepsis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Acronyms SCIENS
  • Sponsors InflaRx
  • Most Recent Events

    • 22 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 28 Jan 2016 Top-line results published in an InflaRx media release.
    • 19 Nov 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTerials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top